^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + adavosertib (AZD1775) (WEE1 inhibitor) + PI-103 (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
Excerpt:
...evaluated a panel of small-molecule inhibitors of CDK4 (PD0322991), PI3K/AKT/mTOR (PI-103), and Wee1 (MK1775) on the growth and survival of NRAS-mutant melanoma cell lines...In a 3D spheroid assay, the combination of PI-103, MK1775, and PD032291 reduced invasion and survival of M245 melanoma cells compared with each agent alone...
DOI:
10.1158/1535-7163.MCT-12-1003
